YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
[Wall Street New York stock exchange stock market] alexsl Shares of Omeros Corporation (OMER [https://seekingalpha.com/symbol/OMER]) set a new 52-week high on Tuesday after Cantor Fitzgerald upgraded the biotech to Overweight from Neutral,…
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Gregory A. Demopulos Chief Accounting Officer - David J. Borges Chief Regulatory Officer - Catherine A. M…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DLocal Ltd (Symbol: DLO), where a total of 23,399 contracts have traded so far, representing approximately 2.3 million underlying…
Investing.com - U.S. stock index futures pointed higher on Thursday, as investors digested fresh corporate earnings and deal news while continuing to assess the outlook for inflation and interest rates. By 06:19 ET (10:19 GMT), the Dow fut…
September S&P 500 E-Mini futures (ESU26) are up +0.19%, andSeptember Nasdaq 100 E-Mini futures (NQU26) are up +0.10% this morning, buoyed by a drop in oil prices, while investors await crucial U.S. producer inflation data for further clues…
(RTTNews) - Omeros Corporation (OMER), a commercial-stage biotechnology company, on Wednesday reported second-quarter 2026 results that turned to profit, compared with a loss last year, aided by revenue growth driven by YARTEMLEA sales. In…
(RTTNews) - Omeros Corporation (OMER), a commercial-stage biotechnology company, on Wednesday reported second-quarter 2026 results that turned to profit, compared with a loss last year, aided by revenue growth driven by YARTEMLEA sales. In…
Earnings Call Insights: Omeros Corporation (OMER) Q2 2026 MANAGEMENT VIEW * "YARTEMLEA generated $32.2 million in gross sales in its first full quarter on the market," "operations generated $4.1 million of positive cash flow during the qua…
Omeros Corporation Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick…
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core ear…
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi…
[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a rare…
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at newaction@p…
Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple. On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use's (CHMP) review of a marketing auth…
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at newaction@p…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in HF Sinclair Corp (Symbol: DINO), where a total of 31,865 contracts have traded so far, representing approximately 3.2 million unde…
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation, (“Omeros" or the "Company") (NASDAQ: OMER) investors that the firm has initiated an investigation into possible securities fraud, and may file…
Choosing between Heartflow (NASDAQ:HTFL) and Omeros (NASDAQ:OMER) in 2026 requires balancing the rapid revenue growth of an AI diagnostic platform against the high-stakes commercial launch of a new specialty drug. Heartflow provides non-in…
LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ:…
Omeros Corporation (NASDAQ:OMER) is among the best get rich quick stocks to buy right now. On June 26, Brandon Folkes from H.C. Wainwright trimmed the price target on Omeros Corporation (NASDAQ:OMER) to $33 from $40 and reaffirmed a Buy ra…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp (Symbol: OMER), where a total of 11,925 contracts have traded so far, representing approximately 1.2 million underlyin…
[Diagnosis Rett syndrome and tablets on a wooden table.] designer491 Acadia Pharmaceuticals (ACAD [https://seekingalpha.com/symbol/ACAD]) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency, e…
Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique scientific approaches. NovoCure is establi…
Key Points Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and…
Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments. Intellia Therapeutics…
Image source: The Motley Fool. DATE Wednesday, May 13, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chairman & Chief Executive Officer — Gregory Demopulos Chief Accounting Officer — David Borges Chief Regulatory Officer — Catherine Melfi Vice Pr…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
(RTTNews) - Sagimet Biosciences Inc. (SGMT), on Monday announced the appointment of Andreas Grauer as Chief Medical Officer, effective April 20. Eduardo Bruno Martins has retired as CMO and will continue to support the company as an extern…
Omeros Corporation Q4 2025 Earnings Call Summary - Moby Strategic Pivot and Operational Execution The company transitioned to a commercial-stage organization following the late December FDA approval of YARTEMLEA, the first and only treatme…
This article first appeared on GuruFocus. Net Income (Q4 2025): $86.5 million or $1.22 per share. Net Loss (Q3 2025): $30.9 million or $0.47 per share. Net Gain from Zaltnibart Transaction: $237.6 million. Non-GAAP Adjusted Net Income (Q4…
Omeros logo Key Points Omeros closed a deal with Novo Nordisk that delivered a $240 million upfront payment and up to $2.1 billion including milestones, plus tiered royalties, while retaining rights to its MASP‑3 small‑molecule program and…
* Omeros press release [https://seekingalpha.com/pr/20458005-omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results] (OMER [https://seekingalpha.com/symbol/OMER]): Q4 Non-GAAP EPS of $3.14 beats by $2.78. * At Decemb…
– Conference Call Today at 4:30 p.m. ET SEATTLE, March 31, 2026--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended Decem…
The following companies are expected to report earnings after hours on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Nike, Inc. (NKE)is reporting for the quarter ending February 28, 2026. The shoes…
[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus wit…